TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8431046
Drug: Intercostal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal saline solution (control group)
Study: 8431046
Drug: Fixed-schedule intramuscular
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-schedule intramuscular buprenorphine
Study: 29746227
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months)
Study: 29746227
Drug: Dalteparin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6)
Study: 26219538
Drug: FP-Sal novel
Normalized name: salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP-Sal novel mDPI 100 μg-50 μg
Study: 26219538
Drug: FP-Sal novel
Normalized name: salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP-Sal novel mDPI 500 μg-50 μg
Study: 26219538
Drug: Originator device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator device 100 μg-50 μg
Study: 26219538
Drug: Originator device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator device 500 μg-50 μg
Study: 23938309
Drug: Inhaled apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled apomorphine (mean dose 2.3 mg)
Study: 23938309
Drug: Inhaled apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled apomorphine
Study: 21074015
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 0.75 mg, two doses 12 hours apart during the preovulatory phase
Study: 14651283
Drug: MTAD (2-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTAD (2-h treatment)
Study: 26944385
Drug: midazolam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam (0.15 mg/kg)
Study: 26944385
Drug: tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol (1 mg/kg)
Study: 24300544
Drug: 12-week antiretroviral
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week antiretroviral therapy (ART)
Study: 24300544
Drug: 48-week antiretroviral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 48-week antiretroviral therapy (ART)
Study: 12584535
Drug: Varicella vaccine
Normalized name: Varicella vaccine
DrugBank: Varicella zoster vaccine (live/attenuated) (DB10318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varicella vaccine (2-dose regimen)
Study: 10586916
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with treatment failure infected with parasites carrying 16 repeat units
Study: 1806475
Drug: Pyridostigmine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (120 mg, p.o.)
Study: 1806475
Drug: GHRH plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH plus placebo (2 tablets, p.o.)
Study: 6626904
Drug: Routine antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antibiotic prophylaxis after urodynamic investigation
Study: 6626904
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis (implied control)
Study: 27206951
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg subcutaneously every 2 weeks (Q2W)
Study: 22700527
Drug: Treatment on
Normalized name: Canesten Clotrimazole Thrush Treatment Once (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment on days 5 to 10 after hemorrhage
Study: 22700527
Drug: Coiling treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coiling treatment on days 5 to 10 after hemorrhage
Study: 22700527
Drug: Clipping treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clipping treatment on days 5 to 10 after hemorrhage
Study: 22700527
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at 3 to 4 days after hemorrhage
Study: 22700527
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at 5 to 10 days after hemorrhage
Study: 22700527
Drug: Treatment >10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment >10 days after hemorrhage
Study: 17268695
Drug: rHuEPO and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO and ACE inhibitors/ARBs
Study: 17268695
Drug: rHuEPO with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO with other antihypertensives (calcium channel blockers or beta-adrenergic receptor blockers)
Study: 12912816
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg single dose)
Study: 11398172
Drug: Rectal examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal examination as initial screening test
Study: 11398172
Drug: PSA screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA screening only (cut-off of 3.0 ng/ml)
Study: 7767416
Drug: Rectal examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal examination
Study: 2567372
Drug: Pentamidine mesylate
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentamidine mesylate aerosol (4 mg/kg every 2 weeks for the first month then monthly) and zidovudine
Study: 28110468
Drug: Increased breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased breakfast eating during treatment
Study: 28110468
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change or decrease in daily eating frequency
Study: 23255691
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of measles vaccine (study group)
Study: 23255691
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of measles vaccine (control group)
Study: 19050085
Drug: Pentastarch (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentastarch (500 mL - maximum 3 L or 28 mL x kg(‐1))
Study: 16584102
Drug: Behavioural Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Family Therapy (BFT)
Study: 16584102
Drug: Individual usual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual usual treatment
Study: 1841044
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg twice daily for 10 days
Study: 8904618
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg
Study: 30280390
Drug: IV SNF472
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV SNF472 9 mg kg–1 in HD patients
Study: 26624824
Drug: Metformin (≤2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (≤2000 mg/d)
Study: 16581161
Drug: IC41 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC41 peptide vaccine
Study: 16581161
Drug: Poly‐L‐arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly‐L‐arginine
Study: 16581161
Drug: Poly‐l‐arginine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly‐l‐arginine alone
Study: 3741530
Drug: suprofen sustained
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: suprofen sustained release 600 mg tablets
Study: 3741530
Drug: indometacin sustained
Normalized name: indometacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: indometacin sustained release 75 mg capsules
Study: 27310329
Drug: QMF149 (indacaterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: QMF149 (indacaterol maleate/MF, 500/400 μg) via Twisthaler (TH) device with activated charcoal
Study: 27310329
Drug: QMF149 (indacaterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: QMF149 (indacaterol maleate/MF, 500/400 μg) via Twisthaler (TH) device without activated charcoal
Study: 27310329
Drug: Indacaterol maleate
Normalized name: Indacaterol Maleate
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol maleate 300 μg inhaled via Breezhaler (BRZ) device
Study: 27310329
Drug: Mouth rinsing
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth rinsing after inhalation
Study: 24615306
Drug: 60-minute treatments
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-minute treatments 2 times weekly
Study: 24615306
Drug: 60-minute treatments
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-minute treatments 3 times weekly
Study: 24615306
Drug: 30-minute treatments
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-minute treatments
Study: 23545865
Drug: Caudal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal dexmedetomidine (DEX) 0.5 μg/kg and bupivacaine 0.25%, 2.5 mg/kg
Study: 23545865
Drug: Bupivacaine 2.5
Normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 2.5 mg/kg and fentanyl 1 μg/kg
Study: 20152050
Drug: Ketorolac treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac treatment
Study: 16633079
Drug: Prasugrel 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 40 mg LD/7.5 mg MD
Study: 16633079
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg LD/15 mg MD
Study: 16633079
Drug: Prasugrel 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 7.5 mg MD
Study: 16633079
Drug: Prasugrel (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (both doses)
Study: 12360154
Drug: Rhythm control
Normalized name: ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY 180 mg in 1 g TOPICAL STICK [ZUSKA RHYTHM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythm control with electrical cardioversion and antiarrhythmic drugs (amiodarone or other class III agents)
Study: 12360154
Drug: Rate control
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate control with beta-blockers, digoxin, or pacemaker and AV nodal ablation
Study: 7975851
Drug: Intradermal hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal hepatitis B vaccine (ID-2)
Study: 7975851
Drug: Intramuscular hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hepatitis B vaccine (IM-10)
Study: 7975851
Drug: Intramuscular hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hepatitis B vaccine (IM-2)
Study: 30922849
Drug: Rehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation treatment group (RTG)
Study: 30096441
Drug: Medication reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reminder and symptom management intervention (automated system calling daily for medication reminders and weekly for symptom assessment)
Study: 18728372
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin treatment (Control)
Study: 18728372
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment (before and after)
Study: 16188050
Drug: Aspirin-resistant group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-resistant group
Study: 8563871
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg prednisolone daily
Study: 8563871
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg prednisolone daily
Study: 8563871
Drug: megadose pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: megadose pulsed steroid therapy (500 or 1000 mg hydrocortisone-21-sodium succinate or methylprednisolone intravenously once a day)
Study: 2514981
Drug: High-dose L-deprenyl
Normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose L-deprenyl (up to 40 mg/day)
Study: 2514981
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of deprenyl (10 mg/day)
Study: 335093
Drug: High-dose terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose terbutaline sulfate (1.5 mg)
Study: 335093
Drug: Low-dose terbutaline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose terbutaline sulfate (0.75 mg)
Study: 335093
Drug: Isoproterenol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol (0.3 mg)
Study: 27427555
Drug: Low-energy shock-wave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy shock-wave therapy (LESWT)
Study: 27427555
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LESWT and BMSC transplantation
Study: 26011919
Drug: Dieting (reduced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dieting (reduced daily intake by 500 kilocalories)
Study: 23065432
Drug: Extended daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended daily hemodialysis (EHD)
Study: 16624773
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 4 mg before operation and 80 microg/h for 48 h after operation
Study: 16624773
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of normal saline before operation and 0.15% ropivacaine 2.0 ml/h for 48 h after operation
Study: 11411461
Drug: D,L-fenfluramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: D,L-fenfluramine (100 mg po)
Study: 26866979
Drug: 7-day dolutegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day dolutegravir functional monotherapy
Study: 23357764
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil (1,500 mg)
Study: 15781543
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 15% magnesium sulfate (12.4 mmol) plus 3 mg/kg lidocaine 0.5% diluted with saline to a total of 40 mL in group M
Study: 15781543
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of saline plus 3 mg/kg lidocaine 0.5% diluted with saline to a total of 40 mL in group C
Study: 14632754
Drug: Thymosin alpha
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha 1 (3.2 mg subcutaneous injections twice weekly for 12 weeks)
Study: 14632754
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no injections for 12 weeks)
Study: 8721025
Drug: rHuEPO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO at a dose of 150 IU/L
Study: 8721025
Drug: rHuEPO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO at a dose of 250 IU/L
Study: 8721025
Drug: rHuEPO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO at a dose of 400 IU/L
Study: 8721025
Drug: Initial EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial EPO levels < 100 IU/L
Study: 8721025
Drug: Initial EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial EPO levels > 100 IU/L
Study: 1760823
Drug: Slow-release isosorbide-5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slow-release isosorbide-5-mononitrate (IS-5-MN), 25 mg once daily
Study: 1760823
Drug: Bupranolol, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupranolol, 50 mg once daily
Study: 1760823
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IS-5-MN and bupranolol
Study: 1760823
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (IS-5-MN and bupranolol)
Study: 6123810
Drug: Clobazam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (20 mg or 30 mg per day)
Study: 24118351
Drug: Dual-wavelength laser
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-wavelength laser system treatment (pulsed dye laser and Nd:YAG)
Study: 9609894
Drug: Liquid meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid meal (5 mg per kilogram of body weight)
Study: 7005122
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg atenolol
Study: 21376161
Drug: 17-hydroxyprogesterone caproate
Normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-hydroxyprogesterone caproate (17Pc), 250 mg weekly injections starting at 16-24 weeks until 34 weeks
Study: 17429083
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg subcutaneously once daily for 13 weeks)
Study: 30313028
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy with phototherapy sessions
Study: 23704845
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted dietary approach and exercise program, delivered through 24 group sessions, with daily food intake and physical activity recording.
Study: 19909550
Drug: Specific oncological
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific oncological treatment of relapse
Study: 16780811
Drug: Sarcosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcosine (2 g/day) added to clozapine
Study: 8777117
Drug: i.v. diamorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. diamorphine infusions
Study: 8777117
Drug: s.c. diamorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. diamorphine infusions
Study: 27022636
Drug: Non‐occluding provisional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐occluding provisional acrylic reinforced prosthesis within 24 h after implant placement
Study: 23426385
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid (10‐mg/kg‐1 bolus and 10‐mg/kg‐1/h‐1 maintenance dose)
Study: 12502673
Drug: Isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 5 mg o.d.
Study: 10552325
Drug: Side-shift therapy
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side-shift therapy (mean treatment duration 2.2 years)
Study: 10552325
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment (historical cohort, mean brace treatment 3.0 years)
Study: 20666678
Drug: Adapalene-BPO combination
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene-BPO combination gel
Study: 19746769
Drug: Adapalene monotherapy
Normalized name: Adapalene
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene monotherapy
Study: 19746769
Drug: BPO monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPO monotherapy
Study: 17324827
Drug: Gel vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel vehicle
Study: 9553291
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated varicella vaccine combined with standard measles-mumps-rubella vaccine
Study: 7378989
Drug: Melphalan (MEL)
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan (MEL) 0.2 mg/kg/day for five days every four weeks
Study: 7378989
Drug: Melphalan (MEL)
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan (MEL) plus 5-fluorouracil (FU) 15 mg/kg/day for five days every four weeks
Study: 7378989
Drug: Melphalan (MEL)
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan (MEL) plus 5-fluorouracil (FU) and dactinomycin (AC) 0.5 mg daily for five days every four weeks
Study: 7378989
Drug: Cytoxan (CY)
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytoxan (CY) 7 mg/kg/day, FU 8 mg/kg/day and AC 0.5 mg/day for five days every four weeks
Study: 30893159
Drug: 1.5-mL reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5-mL reconstitution of abobotulinumtoxinA (50 units)
Study: 30893159
Drug: 2.5-mL reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-mL reconstitution of abobotulinumtoxinA (50 units)
Study: 19011503
Drug: Salmeterol metered
Normalized name: salmeterol Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol metered dose inhaler 42 microg BID
Study: 16799816
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate intake (HC) - 9.3 +/- 0 g CHO kg(‐1) day(‐1)
Study: 16799816
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate intake (LC) - 0.6 +/- 0.1 g CHO kg(‐1) day(‐1)
Study: 14719987
Drug: Radiation doses
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation doses ≥40 grays (Gy)
Study: 8712118
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg plus diltiazem ER 60 mg
Study: 8712118
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg plus diltiazem ER 120 mg
Study: 8712118
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg plus diltiazem ER 180 mg
Study: 8712118
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg plus diltiazem ER 240 mg